Back to News
Market Impact: 0.28
Clinical Catalysts Drive Biotech Movers: Opus Genetics, Quantum & More
Source: Nasdaq
Healthcare & BiotechProduct Launches
Biotech and medical-device stocks advanced Wednesday, led by Opus Genetics, which surged more than 27% after reporting positive clinical data. Quantum BioPharma gained after FDA clearance to begin a Phase 2 multiple-sclerosis trial, while Pulse Biosciences also rallied. The developments are positive company-specific clinical and regulatory catalysts, with limited broader market impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.48
Ticker Sentiment
IRD0.00
PLSE0.45
QNTM0.60
More News
- Why Pulse Biosciences Stock Popped Today
- Pharvaris at Wells Fargo conference: oral HAE drug gains ground
- Samsung works to draw iPhone users to its foldables even as Apple enters the market
- Oil Tops $100 on Supply Fears, Apple Faces a Big Test
- Nano-X Imaging (NNOX) Q2 2026 Earnings Call Transcript
- Chewy (CHWY) Q2 2026 Earnings Call Transcript